Novo Nordisk is raging on the stock exchange after lowered forecasts

The news that Novo Nordisk writes down the prospect of both sales. Nevertheless, profitability this year for the second time in just over two months landed as a bomb on the Copenhagen Stock Exchange on Tuesday afternoon.

When the stock exchange closed, Novo Nordisk had backed 23.11 percent, the share’s largest case ever, according to Danish DR. For example, The OMXC20. Furthermore, an index that follows the most traded shares on the Danish stock exchange, was at the same time down over 11 percent – even that an almost record decline for an individual trading day.

As late as the beginning Of May. Similarly, Novo Nordisk expected sales to increase by between 16 and 24 percent this year, calculated constant currency. Consequently, The assessment is now that the increase will land somewhere between 8 and 14 percent. The forecast for the operating novo nordisk raging stock exchange profit has been lowered about the same.

The most important reason is continued tough competition from so -called “mass compounding”. the production of cheap variants of the company’s drug Wegovy and Ozempic used to treat diabetes and obesity.

The American The Medicines Agency FDA has previously allowed the production of such variants due to a lack of drug. But in May that time limit expired. Despite this. the petition has continued, according to Novo Nordisk’s US manager David Moore, who says that the company for an intensive dialogue with the authorities and has submitted over 120 lawsuits against other manufacturers.

“We try in every way to make this a trademarked market again,” he says during a telephone conference with investors.

In addition to the problems with copies. Novo Nordisk also encounters tougher competition from more conventional players such as US drug giant Eli Lilly, who has taken market shares. At novo nordisk raging stock exchange the end of last year. the US drug share rose sharply after a study showed that Eli Lilly’s preparation has given greater weight loss than Novo Nordisk. Shortly thereafter, Novo Nordisk failed to reach expectations in a separate study, which triggered a large breed in the share.

In the shade of Tuesday’s stock exchange race also announced Novo Nordisk that the company received a new CEO. in the form of Maziar Mike Doustdar who most recently comes from Posten as head of international operations. He succeeds Lars Fruergaard Jørgensen, who was petitioned earlier in the summer.

– We will sharpen our focus and be faster, he says.

Read more:

Fatmic drugs attract thousands – so you avoid weight gain afterwards

Ozempic and Wegovy are investigated after death and severe illness